Actelion pays €10 million for option to acquire Trophos

Tuesday 20 July 2010

Actelion AG of Switzerland has paid €10 million for an option to acquire privately-owned Trophos SA of France which is developing drugs for neurodegenerative diseases. Trophos’s drug for amyotrophic lateral sclerosis (ALS) is in Phase 3.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland